Quoin Pharmaceuticals Reports Wider Loss, Reiterates Going Concern Doubt

summarizeSummary

Quoin Pharmaceuticals reported a wider net loss and reiterated going concern doubt in its Q2 2026 10-Q, while highlighting multiple regulatory advances for its lead drug candidate QRX003.

check_boxKey Events · Earnings and Guidance · QNRX

• Going Concern Warning Reiterated

  Management concluded there is substantial doubt about the company's ability to continue as a going concern for at least one year, with cash and investments totaling $10.8 million as of June 30, 2026.

• Net Loss Widens to $10.4M

  Net loss for H1 2026 was $10.4 million, up from $7.5 million in H1 2025, driven by a 59.6% increase in R&D expenses to $7.1 million.

• FDA Clears IND for Peeling Skin Syndrome

  The FDA cleared the IND application for QRX003 in Peeling Skin Syndrome on July 9, 2026, allowing a Phase 2/3 study to begin in H2 2026.

• Japan Orphan Drug Designation Granted

  Japan's MHLW granted Orphan Drug Designation to QRX003 for Netherton Syndrome on June 4, 2026, providing benefits including priority review and 10 years of market exclusivity.

auto_awesomeAnalysis · QNRX · Life Sciences

Quoin Pharmaceuticals' Q2 2026 10-Q reveals a net loss of $10.4 million for the first half of 2026, up from $7.5 million a year earlier, driven by a 59.6% jump in R&D spending to $7.1 million. The company reiterates substantial doubt about its ability to continue as a going concern, with only $10.8 million in cash and investments as of June 30, 2026. Despite positive regulatory milestones for its lead drug QRX003, including FDA clearance for a Peeling Skin Syndrome trial and Japan Orphan Drug Designation, the company has no revenue and will need to raise additional capital to fund operations.